Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, Johnson GL, Miller CR.
McNeill RS, et al. Among authors: schmid rs.
Neuro Oncol. 2017 Oct 19;19(11):1469-1480. doi: 10.1093/neuonc/nox044.
Neuro Oncol. 2017.
PMID: 28379424
Free PMC article.